The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma Meeting Abstract
| Authors: | Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W. S.; Feldman, T. A.; Menne, T.; Belada, D.; Illés, A.; Tobinai, K.; Tsukasaki, K.; Yeh, S. P.; Shustov, A. R.; Hüttmann, A.; Savage, K. J.; Yuen, S.; Zinzani, P. L.; Miao, H.; Bunn, V.; Fenton, K.; Fanale, M. A.; Puhlmann, M.; Truemper, L. |
| Abstract Title: | The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605140 |
| DOI: | 10.1182/blood-2020-134398 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3 -- Source: Wos |
